Plantible Foods Builds on FDA Milestone With Hackathon Push for Rubi Protein Innovation

Plantible Foods continued to build momentum around its Rubi Protein ingredient this week, using an academic hackathon to explore new applications following a recent U.S. FDA “No Questions” letter. At Angelo State University’s annual hackathon, the company challenged student teams to create a “showstopper” product and commercialization plan centered on Rubi Protein.

The winning team, Ethical Solutions, proposed a concept aimed at improving hospital nutrition, highlighting potential use cases in healthcare and institutional food channels. Plantible served as a judge for live investor-style pitches, signaling an interest in testing Rubi Protein’s versatility across multiple categories and end markets.

These efforts come on the heels of FDA acknowledgment for Rubi Protein, an isolated RuBisCO protein that Plantible positions as a highly functional, bioavailable, and sustainable ingredient for food applications. The FDA’s “No Questions” response removes a key layer of regulatory uncertainty and clears a path toward broader commercialization and B2B adoption.

With regulatory risk reduced, Plantible is better positioned to scale from pilot projects to larger commercial deployments, targeting both alternative-protein and mainstream formulations. The company’s messaging points to growing engagement with consumer packaged goods manufacturers and ingredient buyers, who can now evaluate Rubi Protein with greater confidence.

By leveraging university partnerships, Plantible is cultivating an innovation ecosystem around Rubi Protein at relatively low cost, engaging future food scientists, marketers, and entrepreneurs. This approach may help surface novel product concepts, expand potential use cases, and support long-term pipeline development and brand awareness.

Taken together, the FDA milestone and the hackathon initiative strengthen Plantible’s strategic footing in the competitive protein-ingredient market. The week underscored both regulatory progress and early-market ecosystem building, suggesting a more clearly defined commercialization path and improved prospects for Rubi Protein’s eventual scale-up and market penetration.